FACTORS ASSOCIATED WITH MORTALITY OF ELDERLY PATIENTS WITH COVID-19 INFECTION AT M. DJAMIL HOSPITAL, PADANG, WEST SUMATRA, INDONESIA

COVID-19 INFECTION
Roza Mulyana 1 Indonesia , Dwitya Elvira 1 Indonesia , Rose Dinda Martini 1 Indonesia
1 Faculty of Medicine, Universitas Andalas
Link Copied!
Published 2025-12-24
Vol. 7 No. 2 (2025) PAGES 122-132
DOI 10.36566/ijhsrd/Vol7.Iss2/329
Views / Downloads 294 250

Background:

To analyze the factors influencing the mortality incidence of elderly patients with COVID-19 infection in Padang, West Sumatra, Indonesia.

Methods: This is a retrospective study at M. Djamil Hospital, Padang. Data was collected from the medical records of COVID-19 patients treated during July-September 2021.

Results: Of the 243 elderly patients who experienced COVID-19, the most deaths were male (58.6%) with an average age of 69.64 ± 7.74 years. Multivariate analysis showed that patients with critical-severe clinical symptoms (odds ratio (OR) 12.95; 95% confidence interval (CI) 6.66–25.19), heart disease (OR 6.94; 95% CI 1.63–29.60), respiratory rate ≥30 breaths per minute (OR 3.48; 95% CI 1.04–11.60), pulse ≥100 beats per minute (OR 2.88; 95% CI 1.03–8.04), using a ventilator or high-flow nasal cannula (OR 19.78; 95% CI 5.92–66.10), prothrombin time >13.16 second (OR 12.35; 95% CI 2.43–62.77), interleukin-6 >6 pg/mL (OR 15.19; 95%CI 2.53–91.26), and random blood glucose >199 mg/dL (OR 3.45; 95% CI 1.02–11.68) have a high risk of death.

Conclusion: Elderly patients with COVID-19 infection with critical-severe clinical symptoms accompanied by heart disease, using ventilator or high-flow nasal cannula, longer prothrombin time, high level of interleukin-6, and random blood glucose have higher risk of mortality.

FACTORS ASSOCIATED WITH MORTALITY OF ELDERLY PATIENTS WITH COVID-19 INFECTION AT M. DJAMIL HOSPITAL, PADANG, WEST SUMATRA, INDONESIA : COVID-19 INFECTION. (2025). INDONESIAN JOURNAL OF HEALTH SCIENCES RESEARCH AND DEVELOPMENT (IJHSRD), 7(2), 122-132. https://doi.org/10.36566/ijhsrd/Vol7.Iss2/329
Download data is not yet available.
  1. 1. Akbar MI, Nurmaladewi N, Aspian P, Pagala I, Rustam M. Assessing the service quality at health service facilities during the COVID-19 pandemic in North Buton District, Indonesia. Public Health of Indonesia. 2022 Dec 13;8(4):116-22.
  2. 2. West Sumatra Province. Data pantauan COVID-19 Provinsi Sumatera Barat 2022 [2022 West Sumatra Province COVID-19 monitoring data]. 2022; https://corona.sumbarprov.go.id.
  3. 3. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: A systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infectious Diseases 2021; 21(1):855. https://doi.org/10.1186/s12879-021-06536-3.
  4. 4. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus–infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061-9. https://doi.org/10.1001/jama.2020.1585.
  5. 5. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. The Lancet Respiratory Medicine 2020;8(5):475-81. https://doi.org/10.1016/S2213-2600(20)30079-5.
  6. 6. Iftimie S, López-Azcona AF, Vicente-Miralles M, et al. Risk factors associated with mortality in hospitalized patients with SARS-CoV-2 infection: A prospective, longitudinal, unicenter study in Reus, Spain. PloS One 2020;15(9):e0234452. https://doi.org/10.1371/journal.pone.0234452.
  7. 7. Abul Y, Leeder C, Gravenstein S. Epidemiology and clinical presentation of COVID-19 in older adults. Infect Dis Clin N Am 2023;37:1–26.
  8. 8. Goldberg EM, Southerland LT, Meltzer AC, et al. Age-related differences in symptoms in older emergency department patients with COVID-19: Prevalence and outcomes in a multicenter cohort. J Am Geriatr Soc 2022;70(7):1918–30.
  9. 9. Cohen K, Ren S, Heath K, et al. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ 2022;376:e068414.
  10. 10. Katsoularis I, Fonseca-Rodrı´guez O, Farrington P, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ 2022;377:e069590.
  11. 11. Damayanthi HD, Prabani KI, Weerasekara I. Factors associated with mortality of older people with COVID-19: A systematic review and meta-analysis. Gerontology and Geriatric Medicine 2021;7. https://doi.org/10.1177/23337214211057392.
  12. 12. Shaw AC, Bandaranayake T. Immunology of aging. In Halter JB, Ouslander JG, Studenski S, et al, (Eds.). Hazzard’s geriatric medicine and gerontology 7th ed. New York: McGraw-Hill Education 2017, pp. 33-49.
  13. 13. Gu T, Chu Q, Yu Z, et al. History of coronary heart disease increased the mortality rate of patients with COVID-19: A nested case–control study. BMJ Open 2020;10(9), e038976. https://doi.org/10.1136/bmjopen-2020-038976.
  14. 14. Krishna BA, Metaxaki M, Sithole N, et al. Cardiovascular disease and COVID-19: a systematic review. IJC Heart & Vasculature 2024;54(101482). https://doi.org/10.1016/j.ijcha.2024.101482.
  15. 15. Harrison SL, Buckley BJ, Rivera-Caravaca JM, et al. Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic review. European Heart Journal – Quality of Care and Clinical Outcomes 2021;7:330-9. https://doi:10.1093/ehjqcco/qcab029.
  16. 16. Gopalan N, Senthil S, Prabakar NL, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care—an experience from South India. PloS One 2022; 17(2): e0263471. https://doi.org/10.1371/journal.pone.0263471.
  17. 17. Lee JY, Kim HA, Huh K, et al. Risk factors for mortality and respiratory support in elderly patients hospitalized with COVID-19 in Korea. J. Korean Med. Sci. 2020;35(23):e223. https://doi.org/10.3346/jkms.2020.35.e223.
  18. 18. AbuRuz S, Al-Azayzih A, ZainAlAbdin S, et al. Clinical characteristics and risk factors for mortality among COVID-19 hospitalized patients in UAE: Does ethnic origin have an impact? PloS One 2022;17(3): e0264547. https://doi.org/10.1371/journal.pone.0264547.
  19. 19. De Terwangne C, Sorgente A, Tortora R, et al. Mortality rate and predictors among patients with COVID-19 related acute respiratory failure requiring mechanical ventilation: a retrospective single centre study. J Crit Care Med (Targu Mures) 2021;7(1);21-7. https://doi: 10.2478/jccm-2020-0043.
  20. 20. Rao AV, Cohen HJ. Oncology and aging: general principles. In Halter JB, Ouslander JG, Studenski S, et al. (Eds.). Hazzard’s geriatric medicine and gerontology,7th ed. New York: McGraw-Hill Education 2017, pp. 1423-40.
  21. 21. Avila-Nava A, Cortes-Telles A, Torres-Erazo D, et al. Serum IL-6: A potential biomarker of mortality among SARS-CoV-2 infected patients in Mexico. Cytokine 2021;143: 155543. https://doi.org/10.1016/j.cyto.2021.155543.
  22. 22. Hafez W, Nasa P, Khairy A, et al. Interleukin-6 and the determinants of severe COVID-19: a retrospective cohort study. Medicine 2023;102(45):p e36037. https://DOI: 10.1097/MD.0000000000036037.
  23. 23. Liu X, Wang H, Shi S, et al. Association between IL-6 and severe disease and mortality in COVID-19 disease: A systematic review and meta-analysis. Postgraduate Medical Journal 2022; 98(1165):871-9. https://doi.org/10.1136/postgradmedj-2021-139939.
  24. 24. Akbari H, Tabrizi R, Lankarani KB, et al. The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Life Sci. 2020;258:118167. https://doi: 10.1016/j.lfs.2020.118167.
  25. 25. Cifaldi L, Prencipe G, Caiello I, et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis & Rheumatology 2015; 67(11): 3037-46. https://doi.org/10.1002/art.39295.
  26. 26. Permana H, Huang I, Susandi E, et al. The association of admission random blood glucose concentration and body-mass index with mortality in COVID-19 patients. Eur. Rev. Med. Pharmacol. Sci. 2021;25(22): 7144-50. https://doi.org/10.26355/eurrev_202111_27268.
  27. 27. Mirabella S, Gomez-Paz S, Lam E, et al. Glucose dysregulation and its association wirh COVID-19 mortality and hospital length of stay. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2022;102439. https://DOI: 10.1016/j.dsx.2022.102439.
  28. 28. Gianchandani R, Esfandiari NH, Ang L, et al. Managing hyperglycemia in the COVID-19 inflammatory storm. Diabetes 2020; 69(10):2048-53. https://doi.org/10.2337/dbi20-0022.
  29. 29. Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID‐19 pandemic. J. Med. Virol. 2020; 92(7): 770-5. https://doi.org/10.1002/jmv.25887.
  30. 30. Kohio HP, Adamson AL. Glycolytic control of vacuolar-type ATPase activity: A mechanism to regulate influenza viral infection. Virology 2013;444(1-2):301-9. https://doi.org/10.1016/j.virol.2013.06.026.
  31. 31. Long H, Nie L, Xiang X, et al. D-Dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis. BioMed Res. Int. 2020;6159720. https://doi.org/10.1155/2020/6159720.

Copyright (c) 2025 INDONESIAN JOURNAL OF HEALTH SCIENCES RESEARCH AND DEVELOPMENT (IJHSRD)

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Copyright Rights & Permissions Guide

Reproducing Published Material from other Publishers

It is absolutely essential that authors obtain permission to reproduce any published material (figures, schemes, tables or any extract of a text) which does not fall into the public domain, or for which they do not hold the copyright. Permission should be requested by the authors from the copyright holder (usually the Publisher, please refer to the imprint of the individual publications to identify the copyright holder).

Permission is required for:

  1. Your own works published by other Publishers and for which you did not retain copyright.
  2. Substantial extracts from anyones’ works or a series of works.
  3. Use of Tables, Graphs, Charts, Schemes and Artworks if they are unaltered or slightly modified.
  4. Photographs for which you do not hold copyright.

Permission is not required for:

  1. Reconstruction of your own table with data already published elsewhere. Please notice that in this case you must cite the source of the data in the form of either “Data from…” or “Adapted from…”.
  2. Reasonably short quotes are considered fair use and therefore do not require permission.
  3. Graphs, Charts, Schemes and Artworks that are completely redrawn by the authors and significantly changed beyond recognition do not require permission.

Obtaining Permission

In order to avoid unnecessary delays in the publication process, you should start obtaining permissions as early as possible. If in any doubt about the copyright, apply for permission. JNH cannot publish material from other publications without permission.

The copyright holder may give you instructions on the form of acknowledgement to be followed; otherwise follow the style: “Reproduced with permission from [author], [book/journal title]; published by [publisher], [year].’ at the end of the caption of the Table, Figure or Scheme.

Every mansucript should be accompanied by "Copyright Transfer Agreement" prior to the article publication

Dimension Badge

Downloads

Downloads
Crossmark Badge
Crossmark Badge
Section
Articles
Keywords
COVID-19 elderly mortality Public Health Health

Similar Articles

51-60 of 169

You may also start an advanced similarity search for this article.